Threshold to get $30M from Merck KGaA for pancreatic cancer drug trial

01/28/2013 | American City Business Journals

Merck KGaA will pay Threshold Pharmaceuticals a $30 million milestone fee for initiating a Phase III trial of investigational treatment TH-302 in combination with gemcitabine in patients with previously untreated metastatic pancreatic cancer. The trial will involve 660 patients and the main endpoint will be overall survival. TH-302 is also in a late-stage trial against soft tissue sarcoma.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ